Minocycline Treatment in Acute Hemorrhagic Stroke
Recruitment status was Not yet recruiting
The investigators will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.
Poor Performance Status
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Minocycline Treatment in Acute Hemorrhagic Stroke for Evaluation of Treatment Efficacy and Blood Brain Barrier Permeability|
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||July 2012|
|Estimated Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Minocycline, a semisynthetic second generation derivative of tetracycline, was shown to have a clear beneficial neuroprotective effect in animal models of multiple sclerosis, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Animal models provide promising evidence of minocycline's ability to improve outcomes in an animal stroke model.
In light of these findings, we will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01388127
|Edith Wolfson Medical Center||Not yet recruiting|
|Holon, Israel, 58100|
|Contact: Yair Lampl, MD 972-3-5028512 ext 8512 email@example.com|
|Principal Investigator: Yair Lampl, MD|
|Principal Investigator:||Yair Lampl, MD||Edith Wolfson Medical Center|